The poster presentation will highlight three partner-published studies using the Tropis ® Intradermal (ID ... academic professionals to explore the rapidly advancing science and business of mRNA ...
FDA confirmed in a recent FDA Type B meeting under RMAT designation that the PROACT 1 Phase 3 study could be sufficient to support a full U.S. regulatory approval of rilparencel; ...
WALTHAM, Mass. and BOULDER, Colo., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined ...
Successfully delivered AI de novo designed antibody sequences to AstraZeneca, fulfilling first milestone under collaboration Entered into collaboration with Twist Bioscience to design a novel antibody ...
REMAIN-1 weight maintenance pivotal study enrollment progressing rapidly; mid-point data analysis expected in Q2 2025 ...
Phase 2b clinical trial (ELPIS II) evaluating Lomecel-B™ in rare pediatric disease HLHS has achieved more than 80% enrollmentPositive Type C ...
Equillium Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders ...
Reported 100% of Acute Myeloid Leukemia (AML) patients treated in INB-100 remain in complete remission (CR) at the 2024 European Hematology ...
I was surprised to learn that, according to an Oxford index tracking global student mobility, 69 per cent of Indian students ...
A poster containing additional data was also shared at this event, a copy of which can be found on Absci's website. Absci continues to advance ABS-101 through IND-enabling studies ... our expectations ...
Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ETCompany ParticipantsMarissa Bych - Gilmartin GroupMaria Sainz ...
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q3 2024 Earnings Call Transcript November 9, 2024 Operator: Good afternoon, everyone, and welcome to the Atea Pharmaceuticals Third Quarter 2024 Financial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback